Last reviewed · How we verify
Glucagon Nasal Powder [Baqsimi]
Glucagon Nasal Powder [Baqsimi] is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 1 development. Also known as: LY900018, Baqsimi.
At a glance
| Generic name | Glucagon Nasal Powder [Baqsimi] |
|---|---|
| Also known as | LY900018, Baqsimi |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucagon Nasal Powder [Baqsimi] CI brief — competitive landscape report
- Glucagon Nasal Powder [Baqsimi] updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Glucagon Nasal Powder [Baqsimi]
What is Glucagon Nasal Powder [Baqsimi]?
Glucagon Nasal Powder [Baqsimi] is a Small molecule drug developed by Eli Lilly and Company.
Who makes Glucagon Nasal Powder [Baqsimi]?
Glucagon Nasal Powder [Baqsimi] is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).
Is Glucagon Nasal Powder [Baqsimi] also known as anything else?
Glucagon Nasal Powder [Baqsimi] is also known as LY900018, Baqsimi.
What development phase is Glucagon Nasal Powder [Baqsimi] in?
Glucagon Nasal Powder [Baqsimi] is in Phase 1.
Related
- Manufacturer: Eli Lilly and Company — full pipeline
- Also known as: LY900018, Baqsimi
- Compare: Glucagon Nasal Powder [Baqsimi] vs similar drugs
- Pricing: Glucagon Nasal Powder [Baqsimi] cost, discount & access